Verónica Seija1, Julio César Medina Presentado2, Inés Bado3, Romina Papa Ezdra3, Noelia Batista1, Claudia Gutierrez1, Mariana Guirado2, Macarena Vidal2, Marcelo Nin4, Rafael Vignoli5. 1. Departamento de Laboratorio Clínico, Área Microbiología, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay. 2. Cátedra de Enfermedades Infecciosas, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay. 3. Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Alfredo Navarro 3051, CP 11600 Montevideo, Uruguay. 4. Centro de Nefrología Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay. 5. Departamento de Bacteriología y Virología, Instituto de Higiene, Facultad de Medicina, Universidad de la República, Alfredo Navarro 3051, CP 11600 Montevideo, Uruguay. Electronic address: rvignoli@higiene.edu.uy.
Abstract
OBJECTIVES: The objective of this study was to describe the microbiological characteristics of an extensively drug-resistant (XDR) isolate of Morganella morganii obtained from a patient with sepsis of urinary origin and to describe the patient's clinical characteristics. We further aimed to perform a literature review of the situation in Latin America regarding Gram-negative bacillus (GNB) carriers of New Delhi metallo-β-lactamase (NDM-1) and qnr genes and current reports on the treatment of infections caused by XDR enterobacteria, with particular attention to colistin-resistant isolates. METHODS: The patient's clinical data were obtained from his medical history. Microbiological identification and susceptibility testing were done using the VITEK 2 Compact System. Resistance genes were detected by PCR and sequencing. RESULTS: Blood and urine cultures grew an M. morganii isolate (Mm4232) harboring NDM-1 and qnrD1. The patient was treated successfully with fosfomycin and double doses of meropenem. There are no previous reports of the use of fosfomycin and meropenem to treat infections by XDR enterobacteria harboring NDM-1 carbapenemase. CONCLUSIONS: This is the first report of qnrD1 in South America. We consider that this report could be helpful to physicians implementing treatments for infections caused by XDR GNB, including colistin-carbapenem-resistant GNB.
OBJECTIVES: The objective of this study was to describe the microbiological characteristics of an extensively drug-resistant (XDR) isolate of Morganella morganii obtained from a patient with sepsis of urinary origin and to describe the patient's clinical characteristics. We further aimed to perform a literature review of the situation in Latin America regarding Gram-negative bacillus (GNB) carriers of New Delhi metallo-β-lactamase (NDM-1) and qnr genes and current reports on the treatment of infections caused by XDR enterobacteria, with particular attention to colistin-resistant isolates. METHODS: The patient's clinical data were obtained from his medical history. Microbiological identification and susceptibility testing were done using the VITEK 2 Compact System. Resistance genes were detected by PCR and sequencing. RESULTS: Blood and urine cultures grew an M. morganii isolate (Mm4232) harboring NDM-1 and qnrD1. The patient was treated successfully with fosfomycin and double doses of meropenem. There are no previous reports of the use of fosfomycin and meropenem to treat infections by XDR enterobacteria harboring NDM-1 carbapenemase. CONCLUSIONS: This is the first report of qnrD1 in South America. We consider that this report could be helpful to physicians implementing treatments for infections caused by XDR GNB, including colistin-carbapenem-resistant GNB.
Authors: Jose F Delgado-Blas; Cristina M Ovejero; Lorena Abadia-Patiño; Bruno Gonzalez-Zorn Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Rossana Rosa; Susan D Rudin; Laura J Rojas; Andrea M Hujer; Armando Perez-Cardona; Federico Perez; Robert A Bonomo; Octavio Martinez; Lilian M Abbo; Jose F Camargo Journal: Transpl Infect Dis Date: 2017-11-27 Impact factor: 2.228
Authors: Edwin D Neas; Julie A Dunn; Evelyn Dimaano Silva; A Morgan Chambers; Gary J Luckasen; Adam Jaskowiak Journal: Adv Wound Care (New Rochelle) Date: 2016-10-01 Impact factor: 4.730
Authors: James Albiero; Josmar Mazucheli; Juliana Pimenta Dos Reis Barros; Marcia Maria Dos Anjos Szczerepa; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Serubbabel Sy; Matthew Fidler; Sherwin K B Sy; Maria Cristina Bronharo Tognim Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: D Purkait; A Ahuja; U Bhattacharjee; A Singha; K Rhetso; T K Dey; S Das; R K Sanjukta; K Puro; I Shakuntala; A Sen; A Banerjee; I Sharma; R S Bhatta; M Mawlong; C Guha; N R Pradhan; S Ghatak Journal: Indian J Microbiol Date: 2016-02-11 Impact factor: 2.461